Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Martin Gunnarsson(Örebro University Hospital), Jan Lycke(Sahlgrenska University Hospital), Tomas Olsson(Karolinska University Hospital), Lars Rosengren(Sahlgrenska University Hospital), Niklas Norgren(Umeå University), Clas Malmeström(University of Gothenburg), Markus Axelsson(Sahlgrenska University Hospital), Peter Sundström(Umeå University), Charlotte Dahle(Linköping University), Fredrik Piehl(Karolinska University Hospital), Magnus Vrethem(Linköping University Hospital), Anders Svenningsson(Karolinska Institutet)
Cited by 347
Related Papers
Multiple sclerosis
|Nature Reviews Disease Primers|2018|1.4k
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
A multicentre validation study of the diagnostic value of plasma neurofilament light
|Nature Communications|2021|554
Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF
|Journal of Neurochemistry|1996|502